Cowen reissued their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note published on Friday. They currently have a $163.00 price target on the biopharmaceutical company’s stock.
A number of other research firms have also recently weighed in on ALXN. Raymond James Financial reaffirmed an outperform rating and issued a $130.00 price objective (down previously from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. UBS Group cut shares of Alexion Pharmaceuticals from a strong-buy rating to an outperform rating in a report on Thursday, January 4th. Credit Suisse Group reaffirmed an outperform rating and issued a $147.00 price objective on shares of Alexion Pharmaceuticals in a report on Thursday, January 18th. BidaskClub raised shares of Alexion Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, December 27th. Finally, Evercore ISI raised shares of Alexion Pharmaceuticals from an in-line rating to an outperform rating in a report on Monday, February 5th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and twenty have issued a buy rating to the stock. Alexion Pharmaceuticals has an average rating of Buy and an average target price of $154.64.
Alexion Pharmaceuticals (ALXN) opened at $127.08 on Friday. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. The firm has a market cap of $28,170.00, a price-to-earnings ratio of 58.56, a price-to-earnings-growth ratio of 1.16 and a beta of 1.13.
In related news, CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the sale, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30. Following the sale, the senior vice president now directly owns 32,635 shares of the company’s stock, valued at approximately $3,826,780.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 31,253 shares of company stock valued at $3,656,229. 4.35% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ALXN. Delpha Capital Management LLC purchased a new stake in Alexion Pharmaceuticals during the 4th quarter valued at about $102,000. Valeo Financial Advisors LLC purchased a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at about $147,000. CNB Bank acquired a new position in Alexion Pharmaceuticals in the 4th quarter valued at about $150,000. Dupont Capital Management Corp acquired a new position in Alexion Pharmaceuticals in the 3rd quarter valued at about $156,000. Finally, BT Investment Management Ltd acquired a new position in Alexion Pharmaceuticals in the 3rd quarter valued at about $165,000. 95.38% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Cowen Reiterates “Buy” Rating for Alexion Pharmaceuticals (ALXN)” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://sportsperspectives.com/2018/03/13/cowen-reiterates-buy-rating-for-alexion-pharmaceuticals-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.